Compare VTRS & EXPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | EXPD |
|---|---|---|
| Founded | 1961 | 1979 |
| Country | United States | United States |
| Employees | 30000 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Oil Refining/Marketing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 19.6B |
| IPO Year | 2019 | 1995 |
| Metric | VTRS | EXPD |
|---|---|---|
| Price | $16.55 | $156.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 11 |
| Target Price | $13.50 | ★ $133.00 |
| AVG Volume (30 Days) | ★ 12.4M | 990.6K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.21% | 1.03% |
| EPS Growth | N/A | ★ 4.02 |
| EPS | 0.15 | ★ 1.71 |
| Revenue | ★ $14,299,900,000.00 | $6,920,948,000.00 |
| Revenue This Year | $4.41 | $2.71 |
| Revenue Next Year | $1.96 | $3.74 |
| P/E Ratio | $110.03 | ★ $91.23 |
| Revenue Growth | N/A | ★ 13.49 |
| 52 Week Low | $8.19 | $109.90 |
| 52 Week High | $17.53 | $167.19 |
| Indicator | VTRS | EXPD |
|---|---|---|
| Relative Strength Index (RSI) | 63.17 | 60.34 |
| Support Level | $9.82 | $138.55 |
| Resistance Level | N/A | $165.83 |
| Average True Range (ATR) | 0.57 | 4.37 |
| MACD | 0.06 | 0.58 |
| Stochastic Oscillator | 64.84 | 96.51 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.